Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K/AKT/mTOR pathway is frequently activated in lymphoma, driving tumorigenesis via enhanced protein synthesis.
• Dysregulation of translation initiation factors, including eIF4A and the eIF4F complex, is a key mechanism in lymphoma development.
• Targeting mRNA translation represents a potential therapeutic strategy for lymphoma.

Purpose of the Study:

• To evaluate the antiproliferative activity and in vivo efficacy of eFT226, a novel inhibitor of translation.
• To investigate the role of the PI3K/AKT/mTOR pathway and its regulators in mediating sensitivity or resistance to eFT226.
• To identify predictive biomarkers for patient stratification in clinical development.

Main Methods:

• In vitro and in vivo assessment of eFT226's efficacy in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma models.
• Analysis of PI3K/AKT/mTOR pathway activation, eIF4A activity, and PTEN status as potential predictive markers.
• Evaluation of apoptosis and drug efficacy in relation to PTEN mutation and AKT/mTOR signaling.

Main Results:

• eFT226 demonstrated potent antiproliferative activity and significant in vivo efficacy in DLBCL and Burkitt lymphoma models at low doses.
• Sensitivity to eFT226 correlated with eIF4A activation mediated by mTOR signaling.
• PTEN mutations were associated with reduced apoptosis in vitro and diminished in vivo efficacy, linked to AKT activation and PDCD4 degradation.

Conclusions:

• eFT226 exhibits significant therapeutic potential against specific lymphoma subtypes.
• The PI3K/AKT/mTOR pathway and its downstream effectors, particularly eIF4A and PTEN status, are critical determinants of eFT226 response.
• These findings support the use of eIF4A activation and PTEN/PI3K/mTOR pathway status as predictive biomarkers for patient selection in eFT226 clinical trials.